Related Experiment Video
Updated: Jul 11, 2026

Osteopathic Manipulative Treatment as a Useful Adjunctive Tool for Pneumonia
Published on: May 6, 2014
High plasma concentrations of osteopontin in patients with interstitial pneumonia
1Division of Pathogenesis and Disease Control, Department of Infectious Diseases, Faculty of Medicine, Oita University, 1-1 Hasama, Oita 879-5593, Japan. kadota@med.oita-u.ac.jp
Abstract:
Osteopontin (OPN) produced by alveolar macrophages functions as a fibrogenic cytokine in the development of bleomycin (BLM)-induced murine pulmonary fibrosis, and OPN mRNA is expressed on lung tissues from patients with idiopathic pulmonary fibrosis (IPF). The present study investigates plasma OPN levels in human interstitial pneumonia (IP) and their relationships with disease severity by analyzing the correlation between plasma OPN concentrations and pulmonary functions. The concentrations of OPN in plasma were measured in 17 patients with IP, in 9 with sarcoidosis and in 20 healthy controls using an antigen-capture enzyme-linked immunosorbent assay. The concentrations of OPN in plasma were significantly higher in IP patients than in those with sarcoidosis or in controls. Based on a Receiver Operating Characteristic curve analysis, cut-off points between 300 and 380 ng/ml discriminated between IP and control subjects with 100% sensitivity and 100% specificity. In such case, the sensitivity for sarcoidosis decreased (55.5-33.3%) in cut-offs with 100% specificity. Plasma OPN levels inversely and closely correlated with arterial oxygen tension (PaO2) in patients with IP. Immunohistochemically, OPN was localized predominantly in macrophages and airway epithelium. These findings suggest that plasma OPN levels were found to be associated with the presence of IP, and that OPN play an important role in the development of IP.
Insights
Plasma osteopontin (OPN) levels are elevated in interstitial pneumonia (IP) patients, correlating with disease severity. This suggests OPN may be a key biomarker and factor in IP development.
Area of Science:
- Pulmonary Medicine
- Immunology
- Biomarker Discovery
Background:
- Osteopontin (OPN) is implicated as a fibrogenic cytokine in bleomycin-induced pulmonary fibrosis.
- OPN mRNA is detected in lung tissues of idiopathic pulmonary fibrosis (IPF) patients.
- The role of plasma OPN levels in human interstitial pneumonia (IP) requires further investigation.
Purpose of the Study:
- To investigate plasma osteopontin (OPN) levels in patients with interstitial pneumonia (IP).
- To assess the relationship between plasma OPN concentrations and disease severity in IP.
- To analyze the correlation between plasma OPN levels and pulmonary function parameters.
Main Methods:
- Plasma OPN concentrations were measured using an antigen-capture enzyme-linked immunosorbent assay (ELISA).
- Measurements were performed in 17 IP patients, 9 sarcoidosis patients, and 20 healthy controls.
- Receiver Operating Characteristic (ROC) curve analysis was used to determine diagnostic cut-off points.
Main Results:
- Plasma OPN levels were significantly higher in IP patients compared to sarcoidosis patients and healthy controls.
- ROC analysis identified cut-off points (300-380 ng/ml) with 100% sensitivity and specificity for distinguishing IP from controls.
- Plasma OPN levels showed an inverse correlation with arterial oxygen tension (PaO2) in IP patients.
Conclusions:
- Elevated plasma osteopontin (OPN) levels are associated with the presence of interstitial pneumonia (IP).
- OPN may play a significant role in the pathogenesis and development of IP.
- Plasma OPN shows potential as a diagnostic biomarker for IP, correlating with disease severity.
Related Concept Videos
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia II: Pathophysiology
Pneumonia III: Complications and Assessment
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Atypical Pneumonia
Pneumonia I: Introduction
